Drug Targeting Strategy


CD Bioparticles’ services with customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms can help you to solve:

The challenges you might meet:

  • Fast clearance/ fast degradation/ short circulation time of the drugs
  • Unwanted immunogenicity
  • The requirements for further processing the drugs, such as dispersing in, blending in or coating on another phase
  • Low cell-permeability of the drugs
  • Low specificity of the targeting
  • High dosage required for treatment
  • High side-effect of the toxic chemotherapeutic agents
  • Tedious searching and conjugation of receptor-targeting-moieties
  • Low stability or low activity of the drugs after various barriers within a biological system
  • Highly frequent feeding of the drugs
  • The requirements of sustained release, pulse release, and delayed release
  • The requirements of the delivery at specific period, specific location, and specific dosage

Key features:

  • Stability Improvement
    • Process of size and structure re-construction discovery
    • Physical encapsulation discovery
    • PEGylation discovery
  • Active Targeting by Targeting Ligands
    • Conjugatable receptor-targeting-moiety discovery
    • Liposome discovery
    • Cell-targeting exosome engineering
    • Virus vector engineering
    • Protein Toxin engineering
    • Pro-drug engineering
  • Stimuli-Responsive Controlled-Release Nanocarriers
    • Triggered-degradable, conjugation building block discovery
      • Enzyme-responsive degradable nanocarriers and building blocks
      • Chemical-responsive degradable nanocarriers and building blocks
      • Light-responsive degradable nanocarriers and building blocks
      • Electric field responsive degradable nanocarriers and building blocks
      • Shear-stress responsive degradable nanocarriers and building blocks
      • Temperature responsive degradable nanocarriers and building blocks
    • Triggered-dissociable micelles, polymersome, nanogel discovery
      • Enzyme-responsive dissociable nanocarriers and building blocks
      • Chemical-responsive dissociable nanocarriers and building blocks
      • Light-responsive dissociable nanocarriers and building blocks
      • Electric field responsive dissociable nanocarriers and building blocks
      • Shear-stress responsive dissociable nanocarriers and building blocks
      • Temperature responsive dissociable nanocarriers and building blocks
    • Photo-thermal/photo-dynamic/upconversion particle discovery
    • Magnetic particle discovery

Key benefits:

  • The process of size and structure re-construction of the drugs can prolong the circulation time of the drugs
  • Hydrophobic modification of the polar, small drug molecules improves the cell permeability during the passive delivery
  • Hydrolyzable pro-drug prolongs the degradation time to increase the circulation time of the drugs
  • Physical encapsulation systems improve the dispersion and size-regulation of the hardly dissolved drugs
  • Wide coverage of the Antibodies, Aptamers, Affibody, Anticalins, and Adnectins meets your specific cell-membrane-transporter-targeting design
  • Receptor-targeting-moiety modifications increase the uptake rate of the drugs
  • Ready-to-use, reactive-end-group functionalized receptor-targeting-moieties simplifies your preparation procedures for labeling your drugs or your drug-loading cargos
  • Drug-oriented, customized liposome production and formulation improves the delivery efficiency of the drugs, such as nucleic acids, peptides, or molecules
  • Wide coverage of the stimuli-responsive building blocks will be easy for you to develop your ideal controlled delivery system
  • Ready-to-use building blocks and polymer cargo system simplify the preparation of your drug delivery system and promise the reproducibility of your research data
  • GMP promises the quality of products
  • Analytical platforms cover from drug fabrications to in-vitro and in-vivo tests

Drug candidates:

  • Easy-to-degrade API
  • Hardly dissolved, hardly dispersed, crystalized drugs
  • The drugs needed to be further processed, such as dispersion, coating or blending in a new phase
  • Nanoparticles with low targeting efficiency and low targeting specificity
  • Large molecular, peptide or nucleic acid drugs with insufficient cell-permeability
  • Toxic chemotherapeutic agents
  • Nanoparticles with low targeting efficiency and low targeting specificity
  • Programmable delivery
  • Cell specific, or tissue specific targeted delivery conditions
  • Non-invasive therapy or minimally invasive therapy

Quote Request Form

  •  
  •  

Services

Fill out the form below
to receive a quote

GET A QUOTE

Copyright © 2009 - 2020 CD Bioparticles. All rights reserved.
0
Inquiry Basket